Children's Medical Center Corporation

The University of Birmingham

Rosemarie H De Kruyff

Dale T Umetsu

Gordon James Freeman

Petr Illarionov

Hyeryun Choe

Stephanie Jemielity

Ya-Jen Chang

The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors.

Compositions and methods for inhibiting viral entry

The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived fromactivates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3Tcells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived frompartially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.

Methods for the treatment and prevention of inflammatory diseases

Growing community of inventors

Newton, MA, United States of America

Rosemarie H De Kruyff